uniQure N.V. Культура компании

Mr. Matthew Craig Kapusta, also known as Matt, has been the Chief Executive Officer of uniQure N.V. since December 19, 2016 and serves as its Interim Chief Financial Officer. Mr. Kapusta served as a Chief Financial Officer of uniQure N.V. since January 01, 2015. Mr. Kapusta served as an Interim Chief Executive Officer of uniQure N.V. from September 22, 2016 to December 19, 2016. He served as Member of Management Board at uniQure N.V. since June 10, 2015 until June 15, 2016. Mr. Kapusta served as the Senior Vice President of Business Development at AngioDynamics Inc., since November 15, 2011. He served as Vice President at C.E. Unterberg, Towbin. He was employed at FleetBoston Robertson Stephens, Inc. Mr. Kapusta has nearly 20 years of life science industry experience from investment banking and finance, as well as corporate development positions. He served as Vice President of Healthcare Mergers and Acquisitions at Wells Fargo Securities. Mr. Kapusta helped establish the New York Wells Fargo Securities office and helped create its investment banking training program. He has held several positions in the investment banking and equity space, including his role as Managing Director, Healthcare Investment Banking at Collins Stewart and leadership positions at Wells Fargo Securities and Robertson Stephens. He has advised on more than 50 transactions valued at over $6 billion. He served as Vice President of Strategic Planning and Financial Analysis for Smith & Nephew Orthopaedics, he formed the Business Intelligence and Analytics team responsible for developing data-driven insights and understanding of business performance, such as surgeon attrition, sales force productivity and asset efficiency. He served as Vice President of Finance for Smith & Nephew Orthopaedics. Mr. Kapusta also spearheaded strategic and financial planning for Smith & Nephew's global Hips, Knees and Trauma franchises, identifying significant cost efficiencies that were reinvested to fund key strategic initiatives. Mr. Kapusta was a Senior Associate at Robertson Stephens, Inc., and an associate at Painewebber, Inc. Mr. Kapusta was one of two bankers to receive Wells Fargo's 2005 Golden Spoke Award for exceptional performance and contribution. He has been a Director at uniQure N.V. since June 15, 2016. He holds a BBA in finance and Accounting from the University of Michigan and an MBA in finance and business management from New York University. He earned his Certified Public Accountant license in 1996.

Dr. Scott T. McMillan, Ph.D. has been Chief Operating Officer at uniQure N.V. since August 7, 2017. Dr. McMillan is responsible for all current Good Manufacturing Process (cGMP) activities at uniQure and all product development functions. Dr. McMillan served as a Senior Vice President of Quality & Technical Operations at AMAG Pharmaceuticals, Inc., since January 2013. He joined AMAG in March 2008 as Executive Director of Manufacturing Operations and served as its Head of Quality and Vice President of Technical Operations since March 2010. He has more than 25 years of biotechnology experience in quality, process development, scale-up, technology transfer from bench to commercial scale as well as manufacturing operations for a variety of active pharmaceutical ingredients and finished drug products including small molecules, proteins, antibodies and vaccines. He served at AVANT Immunotherapeutics, Inc. Dr. McMillan served as Senior Director of Manufacturing Operations/Process Development at Celldex Therapeutics, Inc. Prior to 2005, he served as Director of Purification Operations at Johnson Matthey Pharmaceutical Materials, Inc. Since 2011, Dr. McMillan has been a business mentor in the Department of Chemical Engineering, or the Department, at Northeastern University and has served on the Department's Industrial Advisory Board since 2010. He has authored or co-authored more than 75 presentations and publications. Dr. McMillan holds Master's Degree in Economics and B.S. in Chemical Engineering from the University of Delaware and a Ph.D. in Chemical Engineering from the Georgia Institute of Technology.

Dr. Sander van Deventer, M.D., Ph.D., is a Managing Partner at Forbion Capital Partners. Dr. van Deventer has been a Venture Partner at ABN AMRO Capital Benelux since 2004. He is a Co-Founder of uniQure N.V. and has been its Chief Scientific Officer and General Manager of Amsterdam since August 7, 2017. He served as Advisor of uniQure N.V. He has been a Scientific Advisor to Amsterdam Molecular Therapeutics (AMT) Holding N.V., since October 2009. He is a part-time Chief Scientific Officer at Amsterdam Molecular Therapeutics (AMT) Holdings N.V. which he co-founded in 1998. He serves as a Consultant to major pharma and to a significant number of large biotech companies. Dr. van Deventer has extensive experience in translational research with particular emphasis on drug development and significant regulatory experience with the European Agency for the Evaluation of Medicinal Products (EMEA) and Food and Drug Administration (FDA). He has significant experience in the medical and life sciences field. Dr. van Deventer is a Professor of Experimental Medicine at the University of Amsterdam Medical School. Dr. van Deventer is a Professor of Translational Gastroenterology Leiden University Medical Center. Dr. van Deventer was a General Partner at Forbion Capital Partners. He served as Interim Chief Executive Officer at uniQure N.V. from February 2009 to October 2009. He served as a Venture Partner of AAC Capital Partners (ABN AMRO Capital) in 2004. He served as an Interim Chief Executive Officer at Dezima Pharma B.V. Dr. van Deventer has held a critical role in the development of the first commercial monoclonal antibody (Remicade) and the first gene therapy to be granted market authorization in the Western world (Glybera). He was Interim Chief Executive Officer of Amsterdam Molecular Therapeutics (AMT) Holdings N.V. from February 1, 2009 to October 5, 2009 and served as its Member of Management Board from July 5, 2005 to October 2009 and Member of its Supervisory Board. He used this knowledge to first administer an anti-TNF monoclonal antibody to patients with Crohn's disease. Following graduation, he worked as a Scientist in the Laboratory for Medical Biochemistry, Rockefeller University. Since 1995, Dr. van Deventer served as Director of the Laboratory for Experimental Internal Medicine at the Academic Medical Center in 1995, where he worked on therapeutic signal transduction inhibition, gene therapy, and (genetically engineered) probiotics. Dr. van Deventer has advised the Dutch government on several projects, including the national colorectal screening program and the translational gene therapy program. He serves as Chairman and Member of the Scientific Advisory Board at Amsterdam Molecular Therapeutics (AMT) Holdings N.V. Dr. van Deventer has been a Director at Argos Therapeutics, Inc. since 2001. He has been a Director of enGene, Inc. since January 26, 2015. Dr. van Deventer serves as a Director of Replimune Ltd, gIcare Pharma Inc., Cardoz AB, Merix bioscience and Hookipa Biotech AG. He serves as a Member of Scientific Advisory Board of NovImmune SA and AM-Pharma B.V. He is a Member of the Boards of Staten Biotechnology (Naarden, The Netherlands). He has been Member of Scientific Advisory Board of uniQure N.V.BV since April 2012. From 2001 to 2004, Dr. van Deventer was the Chairman of the Department of Gastroenterology and Hepatology at the Academic Medical Center. He served as a Member of Clinical Advisory Board at ChemoCentryx, Inc. He served as the Chairman of the Anton Meelmeijer Center for Genomics and Proteomics at the University of Amsterdam Medical School. Dr. van Deventer served as Vice Chairman and Director of Borean Pharma ApS. He held positions on the Advisory Boards of the FDA and the EMEA. He served as a Director of uniQure N.V. since 2010 until September 14, 2017. He served as a Member of Supervisory Board at uniQure N.V. since April 2012 until June 15, 2016. He is the author of more than 80 book chapters and 500 peer reviewed scientific papers. Dr. van Deventer is the author of numerous articles and book chapters on inflammatory and infectious diseases and cancer and is the principal investigator for several clinical trials using novel small molecules, peptides, antisense RNA, antibodies and cell therapies. He has organized several large international scientific conferences and under his supervision more than 40 students have completed their Ph.D. thesis. He is trained and Board certified in Internal Medicine and Gastroenterology. He was trained as an Internist and Board Certified Gastroenterologist. Dr. van Deventer completed a Ph.D. thesis on the Mechanisms of Endotoxin-induced Inflammation and on the biological activities of bacterial lipopolysaccharides in humans and received his Medical degree and Ph.D. in biological activities from the University of Amsterdam.

Dr. Deya Corzo, M.D served as Senior Vice President of Research & Developtment, Liver/Metabolism at uniQure N.V. since March 02, 2016 until December 31, 2016. Dr. Corzo served as Senior Vice President and Therapeutic Area Head of Liver/Metabolism at uniQure N.V. since October 21, 2015. Dr. Corzo served as the Vice President of Medical Affairs - United States at uniQure N.V. from April 1, 2014 to October 21, 2015. At uniQure, Dr. Corzo is the medical expert for Glybera, leading the development and implementation of global clinical development strategies and plans for Glybera and medical affairs support in the US. She was the Senior Medical Director at Genzyme from 2001 until 2008, where she played an instrumental role in the development, approval and launch of Myozyme(R) and Lymizyme(R) , both treatments for Pompe disease, acquiring great knowledge in the rare disease field. Subsequently, she worked in the same position for Millennium, where she developed and implemented strategies for the life cycle management of the first-in-class oncology drug Velcade(R) , as well as at Celgene, where from 2012 to 2014 she was Executive Director, Medical Affairs / Oncology. A medical doctor by training, she worked as both pediatrician and geneticist.

Mr. Alec Orphanidis serves as Senior Vice President of Global Commercial Operations at uniQure N.V. Mr. Orphanidis is responsible for all commercial activities at uniQure, including overseeing the launch of the first-ever commercially approved gene therapy product in the EU. He began his career at Lederle Pharmaceuticals, and subsequently moved to Schering-Plough, in severaldifferent commercial roles. Prior to uniQure, he was at Amgen (Europe), where his most recent position was Head of the International Nephrology franchise. Mr. Orphanidis holds a B.Sc. in Electrical Engineering, and an M.B.A. in Marketing & International Business, both from Syracuse University, New York.

Mr. Jonathan Garen, also known as Jon, has been Chief Business Officer of uniQure N.V. since July 7, 2016. Mr. Garen served as Chief Business Officer at Syros Pharmaceuticals, Inc. since April 2015 February 2016. Mr. Garen joined Syros from Actavis, where he served as Assistant Vice President of Corporate Development in 2014. Prior to the acquisition, he was Assistant Vice President of Business Development at Forest where he worked for more than 10 years and closed 11 deals including three products on the market. Prior to Forest, he served as Director in the Global Licensing department at Pharmacia Corporation and he was a founder and Vice President of TechEx.com. He earned his Master's degree in Environmental Sciences from Yale and his B.S. in Physics from the Massachusetts Institute of Technology.

Mr. Paul Firuta, MBA, has been the Chief Commercial Officer of uniQure N.V. since May 3, 2016. As a key member of the leadership team, Mr. Firuta oversees global commercial and portfolio planning, program management. He is a seasoned biotechnology and pharmaceutical executive. He has 25 years of industry experience successfully commercializing products targeting rare diseases. He has significant and highly relevant commercial experience in the rare genetic disease space, overseeing commercial efforts for Cinryze'? for hereditary angioedema (HAE), ideally positions. He served as Chief Commercial Officer of Bio Blast Pharma Ltd. since September 2015. He oversaw in particular, the commercial strategy for Cabaletta (IV trehalose) and leads product candidate set to commence Phase 3 clinical development this year in the United States and Canada. He served as President of US Commercial Operations and Senior Vice President at NPS Pharmaceuticals, Inc. since March 25, 2014 and led the development and execution of the GATTEX sales and marketing plan as well as the commercial launch of NAPTARA. He served as Director of Reimbursement and Managed Care/Vice President of Managed Markets of LEV Pharmaceuticals, Inc. since June 26, 2007. He served as Executive Director of National Accounts and Reimbursement at OraPharma, Inc., a Johnson & Johnson company. Mr. Firuta spent nine years at SmithKline Beecham Pharmaceuticals, where he served as Manager of Business Development and Managed Care. He served as Vice President and General Manager of Americas for ViroPharma, Inc. At ViroPharma, where he was responsible for U.S. commercial operations for CINRYZE and VANCOCIN, representing over $400 million in U.S. revenue. He held commercial leadership positions at SmithKline Beecham Pharmaceuticals (GlaxoSmithKline). Mr. Firuta has a Master of Business Administration from St. Joseph's University and a B.Sc. from King's College, Wilkes-Barre, Pennsylvania.

Dr. Alexander E. Kuta, also known as Alex, Ph.D., has been Senior Vice President of Regulatory Affairs at uniQure N.V. since January 25, 2017. Dr. Kuta served as US Head of Regulatory Affairs and Vice President since February 13, 2014 until September 18, 2016. Dr. Kuta served as Vice President of Global Regulatory Affairs at Lantheus Holdings, Inc. (formerly Lantheus Medical Imaging Inc.) from April 2012 to April 2013. Dr. Kuta leads the regulatory function at Lantheus to ensure compliance with all regulatory standards, develop and advance the regulatory strategy for the marketed products and development candidates. He served as the chief spokesperson of Lantheus Medical with regulatory affairs agencies. Dr. Kuta joined Lantheus with more than 20 years of regulatory affairs and drug development experience, including the U.S. Food and Drug Administration and Genzyme Corporation. He served as Vice President, Regulatory Affairs and Quality Assurance at AMAG Pharmaceuticals, Inc. While at Genzyme, Dr. Kuta held Regulatory Affairs roles of increasing responsibility, including support of the Rare Disease, Biosurgery and Multiple Sclerosis businesses. He served as Chief of the Cytokine and Gene Therapies Branch at the FDA Center for Biologics. Dr. Kuta received a B.S. degree in Biology from St. John's University, a Ph.D. from The Chicago Medical School in Immunology and performed his postdoctoral work at the National Cancer Institute. EMD Serono, Inc.

Dr. Steven L. Zelenkofske, M.D, D.O., F.A.C.C., has been Chief Medical Officer of uniQure N.V. since June 6, 2017. Dr. Zelenkofske has nearly 15 years of clinical research experience within the industry. He served as Vice President and Therapeutic Area Head of Cardiovascular/Metabolism for AstraZeneca. He served as Consultant of Regado Biosciences, Inc. from November 7, 2014 to December 31, 2014. Dr. Zelenkofske served as Chief Medical Officer of Regado Biosciences, Inc. since joining it December 2008 until November 7, 2014. Dr. Zelenkofske served as Senior Vice President of Clinical and Medical Affairs at Regado Biosciences, Inc. from January 2009 to November 7, 2014. Dr. Zelenkofske has led clinical programs for 15 development-stage and commercialized cardiovascular products during his pharmaceutical career and has extensive experience as a principal investigator on a number of important trials in cardiovascular medicine. Most recently, Dr. Zelenkofske served as Vice President, Cardiovascular/Thrombosis Medical Unit - US at Sanofi-Aventis Pharmaceuticals. Dr. Zelenkofske served as Patient Safety Officer and Vice President of Clinical Sciences at Cardiac Rhythm Management (CRM) Group of Boston Scientific Corporation since October 31, 2006. Dr. Zelenkofske led the development and implementation of pre- and post-market clinical strategy that supports Boston Scientific Corp.'s CRM technology and therapy portfolio. He was also responsible for enhancing the internal structure, organization and processes for CRM patient safety. Before joining Boston Scientific CRM, he served as a Senior Director of Novartis Pharmaceuticals, where he held positions of increasing responsibility within its cardiovascular division since 2002. He served as Senior Medical Director, US Clinical Development, Hypertension and CV Section Head. Dr. Zelenkofske also served as Director of CV Research and Clinical Director of Electrophysiology Laboratory at the Heart Care Group, where he was a physician investigator for a number of pivotal cardiovascular clinical trials, including SCD HeFT, COMPANION, MADIT, AVID and MUSTT. He is a practicing electrophysiologist (EP) and serves as an associate professor of medicine at the College of Medicine of the Pennsylvania State University/Hershey Medical Center and for the Philadelphia College of Osteopathic Medicine. Dr. Zelenkofske is an active staff member at Muhlenberg Hospital Center in Bethlehem, Pennsylvania and Lehigh Valley Hospital in Allentown, Pennsylvania. He served as a physician investigator for a number of pivotal cardiovascular clinical trials, including SCD HeFT, COMPANION, MADIT, AVID and MUSTT. He is the author or co-author of numerous articles published in professional journals such as the New England Journal of Medicine, Circulation, American Heart Journal and the European Heart Journal. He is an active member of the American College of Cardiology, Heart Rhythm Society, American Heart Association, Heart Failure Society of America, American Society of Hypertension, American College of Chest Physicians, American College of Osteopathic Internists and several other professional societies. He conducted his graduate medical education at the Philadelphia College of Osteopathic Medicine and is board-certified in internal medicine, cardiology and cardiac electrophysiology. Dr. Zelenkofske earned Bachelor of Science and Master of Science in biochemistry and immunopharmacology at Emory University. Dr. Zelenkofske earned his Medical Degree from the Philadelphia College of Osteopathic Medicine and holds certifications in Clinical Cardiac Electrophysiology, Cardiology and Internal Medicine.